RT Journal Article
T1 Relationship Between Clinical Control, Respiratory Symptoms and Quality of Life for Patients with COPD.
A1 Alcazar-Navarrete, Bernardino
A1 Fuster, Antonia
A1 García Sidro, Patricia
A1 García Rivero, Juan Luis
A1 Abascal-Bolado, Beatriz
A1 Pallarés-Sanmartín, Abel
A1 Márquez, Eduardo
A1 Valido-Morales, Agustin
A1 Boldova Loscertales, Ana
A1 Callejas-Gonzalez, Francisco Javier
A1 Palop, Marta
A1 Riesco, Juan Antonio
A1 Golpe, Rafael
A1 Soler-Cataluña, Juan Jose
A1 Miravitlles, Marc
K1 COPD
K1 control
K1 impact
K1 quality of life
K1 symptoms
AB The concept of clinical control has been proposed as an instrument for evaluating patients with COPD. However, the possible association between clinical control, reduced symptom severity and HRQoL has yet to be confirmed. This multicentre, prospective and observational study was carried out in 15 pulmonology clinics in Spain. The patients were followed up for six months, with a baseline visit (V0), followed by visits at three months (V1) and six months (V2). Clinical control was determined at V1, with the application of both clinical criteria and the COPD assessment test (CAT). All patients reported their symptoms by a validated symptom diary (E-RS) using a portable device, and their HRQoL was assessed using the EQ5D questionnaire. The relationship between clinical control and E-RS and HRQoL during follow-up was assessed with t-test. A total of 126 patients were screened. After application of the inclusion/exclusion criteria, 93 were finally included (mean age 66 ± 8 years, 84.9% male), with a mean FEV1 predicted of 49.8% ± 16.5%. Of these patients, 44 (47.3%) achieved clinical control at V1, according to CAT criteria, and 50 (53.8%), according to clinical criteria. The E-RS scores differed between controlled and uncontrolled patients at all time points, both according to CAT (mean differences of -4.6, -5.6 and -6.2 units at V0, V1 and V2, respectively, p Clinical control in patients with COPD, whether measured by CAT or by clinical criteria, is associated with a lower symptom load and a better HRQoL.
YR 2020
FD 2020-10-28
LK http://hdl.handle.net/10668/16548
UL http://hdl.handle.net/10668/16548
LA en
DS RISalud
RD Apr 5, 2025